In addition, it has been reported that CD47/SIRPA blockade with either SIRPα variants acting as an analogue of anti-CD47 antibody or anti-SIRPA antibody does not effectively induce phagocytosis on its own and requires additional tumor-opsonizing antibodies to be efficacious [39,40,41]. Here, SIRPA is linked to neoplasm.